Current control and future risk in asthma management

Erika Sims, David Price, John Haughney, Dermot Ryan, Mike Thomas

Research output: Contribution to journalArticle

42 Citations (Scopus)
3 Downloads (Pure)

Abstract

Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma.
Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalAllergy, Asthma & Immunology Research
Volume3
Issue number4
Early online date21 Sep 2011
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Asthma
Esophageal Diseases
Medication Adherence
Nebulizers and Vaporizers
Bronchodilator Agents
Gastroesophageal Reflux
Respiratory Tract Infections
Health Personnel
Primary Health Care
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Therapeutics
Obesity
Smoking
Guidelines
Psychology

Cite this

Current control and future risk in asthma management. / Sims, Erika; Price, David; Haughney, John; Ryan, Dermot; Thomas, Mike.

In: Allergy, Asthma & Immunology Research, Vol. 3, No. 4, 10.2011, p. 217-225.

Research output: Contribution to journalArticle

Sims, Erika ; Price, David ; Haughney, John ; Ryan, Dermot ; Thomas, Mike. / Current control and future risk in asthma management. In: Allergy, Asthma & Immunology Research. 2011 ; Vol. 3, No. 4. pp. 217-225.
@article{3556f2b5abb24e2ca147af7a2ebac99c,
title = "Current control and future risk in asthma management",
abstract = "Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma.",
author = "Erika Sims and David Price and John Haughney and Dermot Ryan and Mike Thomas",
year = "2011",
month = "10",
doi = "10.4168/aair.2011.3.4.217",
language = "English",
volume = "3",
pages = "217--225",
journal = "Allergy, Asthma & Immunology Research",
issn = "2092-7355",
publisher = "Korean Academy of Asthma, Allergy and Clinical Immunology",
number = "4",

}

TY - JOUR

T1 - Current control and future risk in asthma management

AU - Sims, Erika

AU - Price, David

AU - Haughney, John

AU - Ryan, Dermot

AU - Thomas, Mike

PY - 2011/10

Y1 - 2011/10

N2 - Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma.

AB - Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma.

U2 - 10.4168/aair.2011.3.4.217

DO - 10.4168/aair.2011.3.4.217

M3 - Article

VL - 3

SP - 217

EP - 225

JO - Allergy, Asthma & Immunology Research

JF - Allergy, Asthma & Immunology Research

SN - 2092-7355

IS - 4

ER -